PCa Commentary | Volume 162 – February 2022
This Commentary gives an update on patient selection and monitoring for prostate cancer active surveillance.
Read MoreSelect Page
Edward Weber, MD, is a retired medical oncologist living in Seattle, Washington. He was born and raised in a suburb of Reading, Pennsylvania. After graduating from Princeton University in 1956 with a BA in History, Dr. Weber attended medical school at the University of Pennsylvania. His internship training took place at the University of Vermont in Burlington.
A tour of service as a Naval Flight Surgeon positioned him on Whidbey Island, Washington, and this introduction to the Pacific Northwest ultimately proved irresistible. Following naval service, he received postgraduate training in internal medicine in Philadelphia at the Pennsylvania Hospital and then pursued a fellowship in hematology and oncology at the University of Washington.
His career in medical oncology was at the Tumor Institute of the Swedish Hospital in Seattle where his practice focused largely on the treatment of patients experiencing lung, breast, colon, and genitourinary cancer and malignant lymphoma.
Toward the end of his career, he developed a particular concentration on the treatment of prostate cancer. Since retirement in 2002, he has authored the PCa Commentary, published by the Prostate Cancer Treatment Research Foundation, an analysis of new developments in the prostate cancer field with essays discussing and evaluating treatment management options in this disease. He is a regular speaker at various prostate cancer support groups around Seattle.
Posted by Edward Weber, MD | Feb 2022
This Commentary gives an update on patient selection and monitoring for prostate cancer active surveillance.
Read MorePosted by Edward Weber, MD | Jan 2022
This Commentary looks at bipolar androgen therapy (BAT) as a treatment option for metastatic castration-resistant prostate cancer (mCRPC).
Read MorePosted by Edward Weber, MD | Dec 2021
This Commentary looks at gene mutations in the BRCA Family and PARP inhibition therapy for advanced prostate cancer.
Read MorePosted by Edward Weber, MD | Nov 2021
This Commentary looks at the application of genomics to therapy selection for patients metastatic hormone-sensitive prostate cancer (mHSPC).
Read MorePosted by Edward Weber, MD | Oct 2021
This Commentary considers the benefits of therapy of the primary tumor in newly diagnosed mHSPC, especially as this patient population grows.
Read More